EGFR and neoplasm: Our in vitro and in vivo experiments showed that the combined targeting of gp130 and EGFR by inhibition of IL11 led to decreased PDL1 expression in tumor cells and restoration of the infiltration of T cells, suggesting a potential immunotherapeutic efficacy of this dual blockade strategy for patients with LCBM.